“We continue to be very well positioned for the long-term. Results from key growth products – including Skyrizi, Rinvoq and Ubrelvy – continue to track ahead of our expectations, our aesthetics portfolio is demonstrating a strong V-shaped recovery, our hematologic-oncology franchise is delivering double-digit growth and we’re advancing numerous attractive late-stage pipeline programs,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “We are also executing effectively on Allergan integration initiatives with synergy and accretion targets tracking well.”
NOTE: this is NOT complete release.
View complete release: